Carisma Therapeutics Announces Appointment Of Michael Klichinsky, PharmD, PhD, As Chief Scientific Officer

April 25, 2022

- Klichinsky, co-founder of Carisma Therapeutics, co-invented the company's proprietary and first-of-its-kind engineered macrophage platform PHILADELPHIA, April 21, 2022 /PRNewswire/ -- Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, has appointed Michael Klichinsky, PharmD, PhD, to the role of Chief Scientific Officer. Klichinsky co-founded the company...

Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology

January 10, 2022

Collaboration will combine Carisma’s engineered macrophage technology with Moderna’s mRNA and LNP technologies to generate and develop in vivo CAR-M therapeutics Multi-year research collaboration funded by Moderna with options for up to twelve targets Carisma to receive $45 million up-front cash payment and investment by Moderna in the form of a $35...

Carisma Therapeutics to Participate in 40th Annual J.P. Morgan Healthcare Conference

January 5, 2022

PHILADELPHIA, Jan. 5, 2022 /PRNewswire/ -- Carisma Therapeutics Inc., a biopharmaceutical pioneer in engineered macrophage-based therapeutics, today announced that Steven Kelly, President and Chief Executive Officer of Carisma, will present at the 40th Annual J.P. Morgan Healthcare Conference. The presentation will take place virtually on January 12, 2022, at 7:30 am ET, and will be accessible to...

Carisma Therapeutics Announces Collaboration with Merck to Evaluate CAR-Macrophages in Combination with KEYTRUDA® (pembrolizumab) in a Clinical Study

December 6, 2021

PHILADELPHIA, December 2, 2021 -- Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that it has entered into a clinical study collaboration with Merck (known as MSD outside the US and Canada) to evaluate their proprietary targeted chimeric antigen receptor macrophages...

Carisma Therapeutics Appoints Sanford Zweifach as Chairman to Board of Directors

November 29, 2021

PHILADELPHIA, November 29, 2021 – Carisma Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that Sanford (Sandy) Zweifach has been appointed to the chairman position for the Board of Directors. Mr. Zweifach joins Carisma as a senior executive with 30 years in the...